

JASON KOLBERT JOINS H.C. WAINWRIGHT AS SENIOR BIOTECHNOLOGY ANALYST

NEW YORK, April 2 , 2018 – H.C. Wainwright & Co., LLC (“HCW”), a leading investment bank focused on capital markets and equity research in the Life Sciences and Biotechnology sectors, is pleased to announce that Jason H. Kolbert has joined the firm as a Managing Director in Biotechnology Equity Research. Mr. Kolbert will focus his coverage across multiple therapeutic areas in biotechnology, specialty pharmaceuticals and medical devices.

Mr. Kolbert joins HCW from Maxim Group where he was Head of Healthcare Equity Research. He has over 15 years of experience as a sell-side analyst in healthcare, having worked previously at Salomon Smith Barney and National Securities. Mr. Kolbert also spent several years on the buy-side at Susquehanna Investment Group as a portfolio manager and senior analyst.

HCW’s Chief Executive Officer, Mark Viklund, commented, “HCW is excited to have Jason join the firm’s equity research group. The biotechnology team at HCW now consists of 10 senior analysts who cover more than 200 life sciences companies across the market cap spectrum. The addition of Jason to the team, with his 20+ years of experience, will enable HCW to significantly increase its capacity to uncover cutting edge technologies in the sector.”

About H.C. Wainwright & Co., LLC

H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions. The H.C. Wainwright team has been the leader in the CMPO (Confidentially Marketed Public Offering), PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. H.C. Wainwright was established in 1868 and is headquartered in New York City.